Belimumab
- Generic Name
- Belimumab
- Brand Names
- Benlysta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 356547-88-1
- Unique Ingredient Identifier
- 73B0K5S26A
- Background
Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE). By binding to BLyS and blocking its intera...
- Indication
In the US, belimumab is indicated to treat active systemic lupus erythematosus (SLE) and active lupus nephritis in patients aged five years and older who are receiving standard therapy. In Europe, belimumab is also used to treat SLE and lupus nephritis but only in adults.
...
- Associated Conditions
- Active Systemic Lupus Erythematosus, Lupus Nephritis
- Associated Therapies
- -
CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 3
- Registration Number
- NCT03591380
- Locations
- 🇺🇸
University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, United States
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
- First Posted Date
- 2017-10-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 292
- Registration Number
- NCT03312907
- Locations
- 🇪🇸
GSK Investigational Site, Vigo (Pontevedra), Spain
Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 10
- Registration Number
- NCT03207958
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT02880852
- Locations
- 🇨🇳
GSK Investigational Site, Suzhou, China
Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT02631538
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle-upon-Tyne, United Kingdom
Belimumab Impacting Transplant Eligibility
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2019-04-22
- Lead Sponsor
- E. Steve Woodle
- Target Recruit Count
- 11
- Registration Number
- NCT02500251
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
Belimumab in Idiopathic Inflammatory Myositis
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 17
- Registration Number
- NCT02347891
- Locations
- 🇺🇸
Northwell Health Divison of Rheumatology, Great Neck, New York, United States
Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 80
- Registration Number
- NCT02119156
- Locations
- 🇰🇷
GSK Investigational Site, Suwon, Kyonggi-do, Korea, Republic of
Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2012-08-22
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Hospital for Special Surgery, New York
- Target Recruit Count
- 20
- Registration Number
- NCT01670565
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy
- First Posted Date
- 2012-06-04
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 14
- Registration Number
- NCT01610492
- Locations
- 🇬🇧
GSK Investigational Site, Whitechapel, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.